Vipin Garg, Altimmune CEO
Altimmune says ‘double G’ drug has even better lean mass preservation data in obesity trial update
ORLANDO – Altimmune is back with a full Phase 2 analysis of its “double G” drug pemvidutide, with the company touting it is much better …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.